Megumi Kondo Selected Research

Megumi Kondo Research Topics

Disease

4	Fibrosis (Cirrhosis) 01/2021 - 01/2019
4	Ischemia 04/2012 - 01/2009
3	Pulmonary Arterial Hypertension 07/2023 - 04/2016
3	Obesity 01/2015 - 01/2009
2	Hypoxia (Hypoxemia) 07/2023 - 04/2016
2	Inflammation (Inflammations) 01/2023 - 01/2022
2	Peritoneal Fibrosis 01/2023 - 01/2020
2	Heart Failure 05/2019 - 01/2019
2	Cardiomegaly (Heart Hypertrophy) 05/2019 - 01/2019
2	Body Weight (Weight, Body) 05/2019 - 01/2019
2	Hypertrophy 05/2019 - 01/2019
1	Rupture 01/2022
1	Abdominal Aortic Aneurysm 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 08/2021
1	Chronic Renal Insufficiency 01/2021
1	Pulmonary Hypertension 01/2021
1	Hypoalbuminemia 01/2021
1	Hypertension (High Blood Pressure) 01/2020
1	Insulin Resistance 01/2020
1	Atherosclerosis 01/2020
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2019
1	Vascular Calcification 08/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Catheter-Related Infections 04/2016
1	Spinal Cord Injuries (Spinal Cord Injury) 02/2015
1	Type 2 Diabetes Mellitus (MODY) 10/2010
1	Vascular Diseases (Vascular Disease) 01/2009
1	Systemic Scleroderma (Systemic Sclerosis) 10/2003

Drug/Important Bio-Agent (IBA)

3	MonocrotalineIBA 01/2021 - 04/2016
2	Proteins (Proteins, Gene)FDA Link 07/2023 - 01/2020
2	InflammasomesIBA 01/2023 - 08/2021
2	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 01/2022 - 01/2020
2	pitavastatin (itavastatin)FDA Link 01/2020 - 05/2011
2	Eicosapentaenoic AcidIBA 08/2017 - 01/2017
2	AdiponectinIBA 10/2010 - 01/2009
1	Pyruvic Acid (Pyruvate)IBA 07/2023
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 07/2023
1	Adenosine Triphosphate (ATP)IBA 07/2023
1	Oxidoreductases (Dehydrogenase)IBA 07/2023
1	Messenger RNA (mRNA)IBA 07/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	SolutionsIBA 01/2023
1	Interleukin-18 (Interleukin 18)IBA 01/2023
1	CytokinesIBA 01/2023
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	Angiotensin IIIBA 01/2022
1	CatalaseIBA 01/2022
1	PPAR alphaIBA 01/2022
1	ZincIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Receptor for Advanced Glycation End ProductsIBA 01/2021
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	LipidsIBA 01/2020
1	LDL CholesterolIBA 01/2020
1	CateninsIBA 01/2020
1	6- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA 05/2019
1	KetonesIBA 05/2019
1	SaltsIBA 05/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2019
1	Interleukin-6 (Interleukin 6)IBA 05/2019
1	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2019
1	Collagen Type IV (Type IV Collagen)IBA 05/2019
1	Natriuretic PeptidesIBA 05/2019
1	Sodium-Glucose Transport ProteinsIBA 05/2019
1	Angiotensin Receptor AntagonistsIBA 01/2019
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2019
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2019
1	Valsartan (Vals)FDA Link 01/2019
1	Neprilysin (Neutral Endopeptidase)IBA 01/2019
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2019
1	sacubitrilIBA 01/2019
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2017
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 04/2016
1	beraprostIBA 04/2016
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 02/2015
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 02/2015
1	Plasminogen Activator Inhibitor 1IBA 01/2015
1	Nifedipine (Adalat)FDA LinkGeneric 04/2012
1	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2011
1	Fenofibrate (CiL)FDA LinkGeneric 10/2010
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2009
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2003

Therapy/Procedure

3	Therapeutics 01/2022 - 10/2003
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2023
1	Surgical Amputation (Amputations) 10/2010
1	Caloric Restriction 01/2009